600572.SS
Strong BuyFull HouseZhejiang CONBA Pharmaceutical Co.,Ltd. · Healthcare · China · $1.6B
CNY 4.31 +1.7% · close 30 Sep · scored 3 Oct
Full House: Strong business, sensible price, market agrees. The rare full house.
Does StockRank work? Each month we publish how every decile did, whichever way it went. See the record →
ABOUT ZHEJIANG CONBA PHARMACEUTICAL CO.,LTD.
Read
Zhejiang CONBA Pharmaceutical Co., Ltd. researches, manufactures, and markets modern Traditional Chinese Medicine, chemical drugs, and health products. The company possesses a diverse portfolio of well-known OTC and prescription brands, with strong distribution channels across Chinese retail pharmacies. It is a leading, state-backed pharmaceutical group with a balanced focus on self-medication and clinical therapies.
FINANCIAL SUMMARY (CNY)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM |
|---|---|---|---|---|---|---|
| Revenue | 6.0B | 6.7B | 6.5B | 6.5B | 2.6% | 6.8B |
| EPS (CNY) | 0.14 | 0.23 | 0.25 | 0.19 | 10.7% | 0.20 |
| Shares | 2.6B | 2.6B | 2.6B | 2.5B | -1.4% | 2.5B |
| Debt | 1.2B | 1.0B | 423.8M | 303.7M | -36.7% | 113.3M |
| Equity | 6.9B | 7.0B | 6.8B | 7.0B | 0.6% | — |
| Op CF | 1.2B | 898.6M | 1.0B | 942.6M | -6.6% | 1.1B |
| Inv CF | -211.1M | -289.1M | -211.5M | -64.5M | — | — |
| Fin CF | -924.7M | -719.1M | -1.9B | -493.5M | — | — |
Calmer than 80% of stocks we rank over the past year (26% a year).
How this is worked out
What it measures: day-to-day price moves over the past year, as a yearly figure, ranked against every stock we cover. Very calm under 20% a year, Calm 20 to 30%, Average 30 to 40%, Bumpy 40 to 55%, Very bumpy above that.
What we found: across about 13,500 stocks in 34 markets (2002 to 2025), past swings were a good guide to the next year's, and bumpier stocks fell further. How much further changed too much between eras to put a number on it.
Calm is not safe: a calm stock can still slide steadily.
Rules fixed before any data was fetched. Describes the chart, not a recommendation.
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of 600572.SS are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| 600572.SS | Zhejiang CONBA Pharmaceutical Co.,Ltd.(you) | $1.6B | 91 | Strong Buy |
| 600420.SS | Shanghai Shyndec Pharmaceutical Co., Ltd. | $1.6B | 91 | Strong Buy |
| 600211.SS | Tibet Rhodiola Pharmaceutical Holding Co. | $1.8B | 90 | Strong Buy |
| 600216.SS | Zhejiang Medicine Co., Ltd. | $1.8B | 90 | Strong Buy |
| 600285.SS | Henan Lingrui Pharmaceutical Co., Ltd. | $1.6B | 87 | Strong Buy |
| 600750.SS | China Resources Jiangzhong Pharmaceutical Co.,Ltd | $2.1B | 92 | Strong Buy |
| 600993.SS | Mayinglong Pharmaceutical Group Co., Ltd. | $1.4B | 87 | Strong Buy |
| 002332.SZ | Zhejiang Xianju Pharmaceutical Co., Ltd. | $1.3B | 89 | Strong Buy |
| 002275.SZ | Guilin Sanjin Pharmaceutical Co., Ltd. | $1.1B | 91 | Strong Buy |
| 1681.HK | Consun Pharmaceutical Group Limited | $1.5B | 99 | Strong Buy |
Peer medians: ROE 4.3% · P/E 27.8x · Gross margin 52.7%
Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.